Cartesian Therapeutics Statistics Share Statistics Cartesian Therapeutics has 26M
shares outstanding. The number of shares has increased by 1.08%
in one year.
Shares Outstanding 26M Shares Change (YoY) 1.08% Shares Change (QoQ) 0.18% Owned by Institutions (%) 24.01% Shares Floating 9.39M Failed to Deliver (FTD) Shares 69 FTD / Avg. Volume 0.1%
Short Selling Information The latest short interest is 2.33M, so 8.97% of the outstanding
shares have been sold short.
Short Interest 2.33M Short % of Shares Out 8.97% Short % of Float 22.53% Short Ratio (days to cover) 44.53
Valuation Ratios The PE ratio is -5.99 and the forward
PE ratio is -2.9.
Cartesian Therapeutics's PEG ratio is
0.06.
PE Ratio -5.99 Forward PE -2.9 PS Ratio 11.92 Forward PS 715.6 PB Ratio -68.21 P/FCF Ratio -14.16 PEG Ratio 0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cartesian Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 9.43,
with a Debt / Equity ratio of -2.06.
Current Ratio 9.43 Quick Ratio 9.43 Debt / Equity -2.06 Debt / EBITDA -0.18 Debt / FCF -0.43 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $589.59K Profits Per Employee $-1.17M Employee Count 66 Asset Turnover 0.09 Inventory Turnover n/a
Taxes Income Tax 287K Effective Tax Rate -0.37%
Stock Price Statistics The stock price has increased by -58.44% in the
last 52 weeks. The beta is 0.38, so Cartesian Therapeutics's
price volatility has been higher than the market average.
Beta 0.38 52-Week Price Change -58.44% 50-Day Moving Average 10.77 200-Day Moving Average 13.44 Relative Strength Index (RSI) 50.34 Average Volume (20 Days) 66,225
Income Statement In the last 12 months, Cartesian Therapeutics had revenue of 38.91M
and earned -77.42M
in profits. Earnings per share was -2.99.
Revenue 38.91M Gross Profit 38.91M Operating Income -43.9M Net Income -77.42M EBITDA -77.14M EBIT -77.14M Earnings Per Share (EPS) -2.99
Full Income Statement Balance Sheet The company has 212.61M in cash and 13.98M in
debt, giving a net cash position of 198.63M.
Cash & Cash Equivalents 212.61M Total Debt 13.98M Net Cash 198.63M Retained Earnings -692.07M Total Assets 388.89M Working Capital 151.14M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -23.67M
and capital expenditures -9.09M, giving a free cash flow of -32.77M.
Operating Cash Flow -23.67M Capital Expenditures -9.09M Free Cash Flow -32.77M FCF Per Share -1.26
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -112.81% and -198.97%.
Gross Margin 100% Operating Margin -112.81% Pretax Margin -198.23% Profit Margin -198.97% EBITDA Margin -198.23% EBIT Margin -112.81% FCF Margin -84.21%
Dividends & Yields RNAC does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for RNAC is $40,
which is 292.5% higher than the current price. The consensus rating is "Buy".
Price Target $40 Price Target Difference 292.5% Analyst Consensus Buy Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 5, 2024. It was a
backward
split with a ratio of 1:30.
Last Split Date Apr 5, 2024 Split Type backward Split Ratio 1:30
Scores Altman Z-Score -2.29 Piotroski F-Score 3
